Esma Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.65 M
- Company Age 34 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 3.99 M
- Revenue Growth -8.21%
- Profit Growth 283.41%
- Ebitda 510.29%
- Net Worth 36.38%
- Total Assets -1.05%
About Esma Formulations
Esma Formulations Private Limited (EFPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 November 1990 and has a history of 34 years and three months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.65 M.
The company has closed loans amounting to ₹3.99 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Shivbhagwan Matanhelia and Saroj Matanhela serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232GJ1990PTC014582
-
Company No.
014582
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Nov 1990
-
Date of AGM
29 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Esma Formulations?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivbhagwan Matanhelia
|
Director | 01-Nov-1990 | Current |
|
Saroj Matanhela
|
Director | 01-Nov-1990 | Current |
Financial Performance of Esma Formulations.
Esma Formulations Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 8.21% decrease. The company also saw a substantial improvement in profitability, with a 283.41% increase in profit. The company's net worth Soared by an impressive increase of 36.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Esma Formulations?
In 2019, Esma Formulations had a promoter holding of 76.92% and a public holding of 23.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹3.99 M
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Aug 2000 | Bank Of Baroda | ₹2.79 M | Satisfied |
| 07 Sep 1998 | Bank Of Baroda | ₹1.20 M | Satisfied |
How Many Employees Work at Esma Formulations?
Unlock and access historical data on people associated with Esma Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Esma Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Esma Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.